Geneva, Switzerland and Boston, MA - May 11, 2017 - ObsEva SA (Nasdaq: OBSV), a Swiss biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy, today announced that it will report financial results for the first quarter ended March 31, 2017 on Thursday, May 18, 2017. ObsEva will host an investment community conference call at 8:00 a.m. Eastern Time (2:00 p.m. Central European Time) on May 18, 2017 to discuss the financial results and provide a corporate update.
Investors may participate in the conference call by dialing 844-419-1772 for U.S. callers and (213) 660-0921 for international callers, with conference ID: 21002537.
Those interested in listening to the conference call live via the internet may do so by visiting the "Investors" page of ObsEva's website at www.obseva.com and clicking on the webcast link.
A webcast replay of the conference call will be available on the "Investors" page of ObsEva's website at www.obseva.com.
ObsEva is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor and improving ART outcomes. ObsEva is listed on The NASDAQ Global Select Market and is trading under the ticker symbol "OBSV". For more information, please visit www.ObsEva.com.
Senior Director, Investor Relations